Cannabidiol (CBD): A novel therapeutic for Alzheimer's disease. [ 2018 - ]

Research Grant

Researchers: A/Pr Tim Karl (Principal investigator) ,  Dr Arne Ittner ,  Prof Brett Garner

Brief description Current drugs do not stop or reverse the progression of Alzheimer’s disease (AD). Also, brains of AD patients show a number of biological changes and effective drugs should target those together. Cannabidiol (CBD) has such abilities when tested in AD cell models. We found that CBD can also prevent and reverse memory deficits in AD mice. We propose to provide convincing preclinical evidence for the benefits of CBD for human AD therapy and to define mechanisms involved.

Funding Amount $775,005.00

Funding Scheme Project Grants

Notes Standard Project Grant